| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Ibrutinib |
| Brand | Imbruvica® |
| Indication | For the treatment of patients with chronic lymphocytic leukaemia who have received ≥1 prior therapy, or as a first-line treatment in the presence of del(17p) or TP53 mutation in patients not suitable for chemoimmunotherapy. |
| Assessment Process | |
| Rapid review commissioned | 07/11/2014 |
| Rapid review completed | 18/12/2014 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 02/04/2015 |
| NCPE assessment completed | 01/10/2015 |
| NCPE assessment outcome | Reimbursement not recommended. |
The cost effectiveness of ibrutinib (Imbruvica®) in the treatment of patients with CLL who have received ≥1 prior therapy, or as a first-line treatment in the presence of del(17p)/TP53 mutation in patients not suitable for chemo-immunotherapy, has not been demonstrated and therefore it is not recommended for reimbursement at the submitted price.
The HSE has approved reimbursement following confidential price negotiations.